These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30232538)

  • 1. Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial.
    McAlister FA; Ye C; Beaupre LA; Rowe BH; Johnson JA; Bellerose D; Hassan I; Majumdar SR
    Osteoporos Int; 2019 Jan; 30(1):127-134. PubMed ID: 30232538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP Trial): A Randomized Controlled Trial.
    Majumdar SR; McAlister FA; Johnson JA; Rowe BH; Bellerose D; Hassan I; Lier DA; Li S; Maksymowych WP; Menon M; Russell AS; Wirzba B; Beaupre LA
    J Bone Miner Res; 2018 Dec; 33(12):2114-2121. PubMed ID: 30040140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study.
    Majumdar SR; Johnson JA; Bellerose D; McAlister FA; Russell AS; Hanley DA; Garg S; Lier DA; Maksymowych WP; Morrish DW; Rowe BH
    Osteoporos Int; 2011 Jan; 22(1):223-30. PubMed ID: 20358359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
    Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
    Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates.
    Ojeda-Bruno S; Naranjo A; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Quevedo JC; Rodríguez-Lozano C
    Osteoporos Int; 2011 Jun; 22(6):1821-8. PubMed ID: 20924747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.
    Naranjo A; Ojeda-Bruno S; Bilbao-Cantarero A; Quevedo-Abeledo JC; Diaz-González BV; Rodríguez-Lozano C
    Osteoporos Int; 2015 Nov; 26(11):2579-85. PubMed ID: 26048675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment.
    Wozniak LA; Johnson JA; McAlister FA; Beaupre LA; Bellerose D; Rowe BH; Majumdar SR
    Osteoporos Int; 2017 Jan; 28(1):219-229. PubMed ID: 27423660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance to The Joint Commission proposed Core Measure set on osteoporosis-associated fracture: review of different secondary fracture prevention programs in an open medical system from 2010 to 2015.
    Fojas MC; Southerland LT; Phieffer LS; Stephens JA; Srivastava T; Ing SW
    Arch Osteoporos; 2017 Dec; 12(1):16. PubMed ID: 28155141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011.
    Dehamchia-Rehailia N; Ursu D; Henry-Desailly I; Fardellone P; Paccou J
    Osteoporos Int; 2014 Oct; 25(10):2409-16. PubMed ID: 24980182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Osteoporosis Interventions to Improve Quality of Care After Upper Extremity Fracture: Results From a Randomized Trial (C-STOP Trial).
    Majumdar SR; Lier DA; McAlister FA; Johnson JA; Rowe BH; Beaupre LA
    J Bone Miner Res; 2019 Jul; 34(7):1220-1228. PubMed ID: 30779861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of osteoporotic fractures--an "OPTIMAL" model of care from Singapore.
    Chandran M; Tan MZ; Cheen M; Tan SB; Leong M; Lau TC
    Osteoporos Int; 2013 Nov; 24(11):2809-17. PubMed ID: 23615816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral bisphosphonates are associated with reduced mortality after hip fracture.
    Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
    Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials.
    Majumdar SR; McAlister FA; Johnson JA; Weir DL; Bellerose D; Hanley DA; Russell AS; Rowe BH
    Osteoporos Int; 2014 Sep; 25(9):2173-9. PubMed ID: 24803330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.